Please ensure Javascript is enabled for purposes of website accessibility

Why Achillion Pharmaceuticals Shares Crashed 37% in January

By Todd Campbell - Feb 4, 2016 at 3:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors continue to sell off the once-promising developer of hepatitis C drugs.

Image source: Achillion Pharmaceuticals.

What: Despite announcing a key new hire last month, shares in the clinical-stage drugmaker Achillion Pharmaceuticals (ACHN) dropped 37.3% in January, according to S&P Capital IQ.

So what: On Jan. 4, Achillion Pharmaceuticals announced it had hired Bristol-Myers Squibb's (BMY 0.76%) former head of discovery chemistry, Joel Barrish, as its chief science officer. The move comes as Achillion Pharmaceuticals attempts to broaden its clinical lineup beyond the hepatitis C drugs it licensed to Johnson & Johnson (JNJ 0.33%) last summer.

In that licensing pact, Johnson & Johnson gained rights to Achillion Pharmaceuticals' promising odalasvir, an NS5A inhibitor that delivered 100% cure rates when used alongside Gilead Sciences' (GILD 0.47%) Sovaldi in treatment durations of as little as six weeks.

In October, Johnson & Johnson initiated phase 2 studies that included odalasvir in combination with its own hepatitis C drugs. The trial is evaluating the ability to cure hepatitis C in about four weeks.

Now what: In licensing its hepatitis C compounds to Johnson & Johnson, Achillion Pharmaceuticals teams up with one of the planet's largest drugmakers and gains the potential to earn up to $1.1 billion in milestones plus royalties. It also got Johnson & Johnson as an equity investor that owns over 18 million shares.

Although the potential associated with Achillion Pharmaceuticals licensing deal is big, the continuing drop in Achillion Pharmaceuticals' shares shows that investors remain underwhelmed.

Ideally, investors would have preferred for Johnson & Johnson to buy Achillion Pharmaceuticals outright, particularly given that many investors worry an odalasvir combination therapy will end up reaching the market too late to win away market share from Gilead Sciences.

Ultimately, only time will tell if investors are right to walk away from Achillion Pharmaceuticals shares, but we should get some additional insight soon when Johnson & Johnson's midstage study wraps up. If results are good, then late-stage studies could potentially lead to a market entry as early as 2018. In the meantime, Achillion Pharmaceuticals' shareholders will have to hope that Barrish can usher along some new drugs into trials that rekindle investor interest.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$178.73 (0.33%) $0.59
Achillion Pharmaceuticals, Inc. Stock Quote
Achillion Pharmaceuticals, Inc.
ACHN
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$76.54 (0.76%) $0.58
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.63 (0.47%) $0.29

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
323%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.